No definition available.
Ependymoma, excluding all cancers (controls excluding all cancers)
C3_EPENDYDOMA_EXALLC
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
60 |
4. Check minimum number of eventsNone |
60 |
5. Include endpointsNone |
60 |
6. Filter based on genotype QC (FinnGen only) |
60 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Ependymoma, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Ependymoma
- Malignant neoplasm of eye, brain and central nervous system
- Malignant neoplasm of eye, brain and central nervous system, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 60 | 36 | 24 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 46.43 | 43.60 | 50.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 54
- Matched controls
- 541
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
9391/3-C72.0
ICD-O-3
Ependymoma, NOS, of spinal cord
+∞
32.6
28
*
H02AB02
ATC
dexamethasone; systemic
154.3
20.1
20
*
ABB10
NOMESCO Finland
Resection of lesion of spinal canal
+∞
16.5
15
*
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
+∞
16.5
15
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
73.9
14.7
16
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
15.8
13.5
23
24
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
167.3
13.0
13
*
130
Kela drug reimbursment
Malignant tumour
+∞
13.0
12
*
C71.74
ICD-10 Finland
Malignant tumor of the brainstem ependyoma
+∞
11.9
11
*
C72.09
ICD-10 Finland
Malignant tumor of the spinal cord other histology
+∞
11.9
11
*
C72.01
ICD-10 Finland
Malignant tumor of the spinal cord grade II glioma
+∞
10.8
10
*
C72.00
ICD-10 Finland
Malignant tumor of the spinal cord without histology
+∞
10.8
10
*
C71.51
ICD-10 Finland
Malignant tumor of cerebral ventricle ependymoma
+∞
9.7
9
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
105.9
8.7
9
*
9391/3-C71.7
ICD-O-3
Ependymoma, NOS, of brain stem
+∞
8.5
8
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
8.5
8
*
D43.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal cord
+∞
8.5
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
18.8
8.2
12
8
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
52.9
8.0
9
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
30.0
7.9
10
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
92.2
7.6
8
*
WF002
NOMESCO Finland
Radical radiotherapy
92.2
7.6
8
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
7.5
7
*
D33.43
ICD-10 Finland
Spinal cord
+∞
7.5
7
*
L28
ICPC
Limited function/disability (L)
7.9
7.0
16
27
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
5.8
6.8
21
53
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
17.1
6.7
10
7
A04AA02
ATC
granisetron; systemic, transdermal
78.8
6.6
7
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
21.1
6.5
9
5
D33.40
ICD-10 Finland
Benign glioma of the spinal cord (grade I)
+∞
6.4
6
*
D33.41
ICD-10 Finland
Myxopapillary epndymoma of the spinal cord (grade I)
+∞
6.4
6
*
D33.4
ICD-10 Finland
Benign neoplasm: Spinal cord
+∞
6.4
6
*
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
+∞
6.4
6
*
ZX050
NOMESCO Finland
Stereotactic radiotherapy
+∞
6.4
6
*
9391/3-C71.5
ICD-O-3
Ependymoma, NOS, of ventricle, NOS
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
37
10.14
16.33
6.3
6.4
0.51
0.87
mmol/l
0.22
15
30
43
196
5.21
8.31
3.5
4.0
—
—
—
0
0
12
24
6.00
6.03
5.3
7.7
0.76
0.86
%
0.38
12
24
12
25
5.75
5.78
5.3
7.5
1.14
1.89
%
0.82
12
25
16
45
4.48
5.49
8.2
12.2
23.88
24.76
mmol/l
0.62
16
45
26
106
3.56
5.31
3.1
2.2
—
—
—
0
0
36
213
2.73
3.49
10.0
4.6
8.83
10.30
umol/l
0.96
36
197
5
5
10.73
3.03
1.8
2.8
27.40
24.20
%
—
5
5
5
6
8.94
2.80
1.6
1.7
—
—
—
0
0
5
6
8.94
2.80
1.8
2.7
—
—
—
0
0
26
389
0.41
2.78
4.0
3.3
—
—
—
0
0
28
160
2.41
2.75
3.4
3.5
—
—
—
0
0
15
63
2.84
2.72
5.8
2.6
29.87
30.32
s
0.13
15
63
5
7
7.65
2.60
1.4
1.6
—
—
—
0
0
5
8
6.69
2.42
1.6
1.1
—
—
—
0
0
5
8
6.69
2.42
1.6
1.1
—
—
—
0
0
6
13
5.00
2.33
4.7
5.6
16.33
21.28
nmol/l
—
6
13
13
55
2.74
2.31
1.8
1.6
—
—
—
0
0
8
27
3.26
2.02
1.5
1.3
—
—
—
0
0
22
136
1.98
1.63
4.0
2.7
2.37
2.36
mmol/l
0.09
22
120
9
39
2.53
1.51
2.0
1.5
—
—
—
0
0
5
17
3.11
1.38
1.6
1.2
—
—
—
0
0
5
18
2.93
1.31
12.8
4.2
2.62
3.49
g/l
—
5
18
8
37
2.34
1.27
8.4
15.8
1.52
1.59
mmol/l
—
8
28
8
37
2.34
1.27
2.1
1.4
—
—
—
0
0
8
38
2.27
1.24
2.0
3.5
—
—
—
0
0
8
40
2.15
1.17
8.4
14.7
5.05
5.03
kpa
—
8
35
55
495
2.33
1.15
18.9
10.9
26.52
17.78
mg/l
0.95
50
359
13
75
1.94
1.14
3.3
3.2
0.80
3.87
e6/l
—
5
37
25
181
1.65
1.04
2.1
3.2
80.12
79.20
nmol/l
0.04
25
160
7
126
0.50
1.03
1.7
1.6
—
—
—
0
0
0
32
0.00
0.98
0.0
1.5
—
—
—
0
0
13
79
1.82
0.98
3.3
3.2
0.40
1.20
e6/l
—
5
41
8
43
1.99
0.92
3.6
7.1
—
—
—
0
0
10
59
1.83
0.81
1.7
4.0
24.49
25.56
%
—
10
54
5
94
0.49
0.74
1.2
1.4
—
—
—
0
0
20
148
1.53
0.72
2.8
3.3
15.30
49.37
ng/l
—
10
90
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
20
0.00
0.61
0.0
1.7
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
19
0.00
0.61
0.0
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.2
—
218.25
—
0
8
10
68
1.56
0.51
5.1
1.7
2.47
2.44
mmol/l
—
10
55
15
114
1.42
0.46
6.5
4.2
0.00
0.00
estimate
—
8
38
20
162
1.35
0.43
2.1
1.9
92.40
100.19
pmol/l
—
10
71
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
21
247
0.77
0.37
6.3
3.7
0.00
0.00
estimate
—
7
36
21
244
0.79
0.32
7.0
5.2
0.00
0.00
estimate
—
8
38
42
390
1.26
0.28
4.9
4.1
14.54
14.65
pmol/l
0.11
42
357
13
105
1.30
0.27
3.7
3.9
0.75
2.46
ug/l
3.89
13
95
15
175
0.81
0.22
6.7
3.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
6
49
1.25
0.21
2.2
1.9
23.83
45.82
u/l
—
6
39
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
0.78
—
0
5
22
241
0.86
0.16
6.1
3.7
0.00
0.00
estimate
—
8
38
44
424
1.14
0.11
18.5
9.5
91.22
85.66
ml/min/173m2
1.08
37
330
6
70
0.84
0.08
1.8
1.9
—
—
—
0
0
7
83
0.82
0.07
2.0
2.0
451.86
464.48
pmol/l
—
7
69
47
474
0.96
0.00
27.3
11.8
40.12
39.92
%
0.09
35
374
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
527.00
—
0
7
0
7
0.00
0.00
0.0
1.0
—
47.43
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
0.80
—
0
5
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
1.8
1.9
—
—
—
0
0
6
59
1.02
0.00
3.5
2.2
0.67
1.04
ug/l
—
6
33
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
358.00
—
0
9
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_EPENDYDOMA_EXALLC – Ependymoma, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).